Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes.

acute tubulointerstitial nephritis autoimmunity myelodysplastic syndromes

Journal

Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 21 12 2020
accepted: 22 12 2020
entrez: 18 3 2021
pubmed: 19 3 2021
medline: 19 3 2021
Statut: epublish

Résumé

Myelodysplastic syndromes (MDS) are characterized by a high prevalence of associated autoimmune manifestations. Kidney involvement has been rarely reported in MDS patients. We report on the spectrum of kidney pathological findings in MDS patients. We retrospectively identified MDS patients who had undergone a kidney biopsy between 2001 and 2019 in nine Swiss and French nephrology centres. Nineteen patients (median age 74 years [63-83]) were included. At the time of kidney biopsy, eleven (58%) patients had extra-renal auto-immune manifestations and sixteen (84%) presented with acute kidney injury. Median serum creatinine at diagnosis was 2.8 mg/dL [0.6-8.3] and median urinary protein to creatinine ratio was 1.2 g/g [0.2-11]. Acute tubulo-interstitial nephritis (TIN) was present in seven (37%) patients. Immunofluorescence study in one patient with acute TIN disclosed intense IgG deposits along the tubular basement membrane and Bowman's capsule. Other kidney pathological features included ANCA-negative pauci-immune necrotizing and crescentic glomerulonephritis (n = 3), membranous nephropathy (n = 2), IgA nephropathy (n = 1), IgA vasculitis (n = 1), immunoglobulin-associated membrano-proliferative glomerulonephritis type I (n=1), crescentic C3 glomerulopathy (n = 1), fibrillary glomerulonephritis (n = 1) and minimal change disease (n = 1). Eleven (58%) patients received immunosuppressive treatments, among whom one developed a severe infectious complication. After a median follow-up of 7 month [1-96], nine (47%) patients had chronic kidney disease stage 3 (n = 6) or 4 (n = 3) and five (26%) progressed to end-stage kidney disease. Three patients died. MDS are associated to several autoimmune kidney manifestations, predominantly acute TIN. MDS are to be listed among the potential causes of autoimmune TIN.

Identifiants

pubmed: 33732989
doi: 10.1016/j.ekir.2020.12.030
pii: S2468-0249(20)31864-7
pmc: PMC7938072
doi:

Types de publication

Journal Article

Langues

eng

Pagination

746-754

Informations de copyright

© 2021 International Society of Nephrology. Published by Elsevier Inc.

Références

Nephron. 1992;62(2):231-2
pubmed: 1436321
Case Rep Oncol Med. 2019 Sep 2;2019:5086963
pubmed: 31565452
Leuk Lymphoma. 2002 Nov;43(11):2083-92
pubmed: 12533032
Nephrol Dial Transplant. 2002 Jul;17(7):1336-8
pubmed: 12105261
Am J Hematol. 2018 Jun;93(6):824-840
pubmed: 29878489
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1741-1750
pubmed: 31685544
Clin J Am Soc Nephrol. 2011 Apr;6(4):775-84
pubmed: 21441134
Br J Haematol. 1995 Oct;91(2):403-8
pubmed: 8547082
Am J Kidney Dis. 2017 Jul;70(1):e3-e4
pubmed: 28646985
Br J Haematol. 2020 May;189(3):393
pubmed: 32026461
J Clin Oncol. 2011 Jul 20;29(21):2897-903
pubmed: 21690473
Am J Kidney Dis. 1998 Feb;31(2):336-40
pubmed: 9469507
Arthritis Care Res (Hoboken). 2011 Aug;63(8):1188-94
pubmed: 21584947
Ann Hematol. 2018 Aug;97(8):1349-1356
pubmed: 29572561
Nephrol Dial Transplant. 2005 Jul;20(7):1392-9
pubmed: 15855209
Br J Haematol. 2009 Nov;147(4):414
pubmed: 19538524
Am J Kidney Dis. 2018 Jul;72(1):84-92
pubmed: 29429752
Kidney Res Clin Pract. 2013 Sep;32(3):134-7
pubmed: 26877929
Medicine (Baltimore). 2016 Mar;95(13):e3091
pubmed: 27043672
Ann Hematol. 2018 Nov;97(11):2015-2023
pubmed: 30091023
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Kidney Int. 2011 Oct;80(7):753-9
pubmed: 21654720
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Semin Arthritis Rheum. 2000 Jun;29(6):360-7
pubmed: 10924021
Rheumatology (Oxford). 2016 Feb;55(2):291-300
pubmed: 26350487
J Am Soc Nephrol. 2020 Feb;31(2):365-373
pubmed: 31919107

Auteurs

Nora Schwotzer (N)

Transplantation Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland.

François Provot (F)

Department of Nephrology and Renal Transplantation, CHRU de Lille, Lille, France.

Simon Ville (S)

Department of Nephrology and Immunology, CHU de Nantes, Nantes, France.

Laurent Daniel (L)

Pathology Department, CHU La Timone, Marseille, France.

Awena Le Fur (A)

Department of Nephrology, CH La Roche-sur-Yon, La Roche-sur-Yon, France.

Sébastien Kissling (S)

Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland.

Noémie Jourde-Chiche (N)

Department of Nephrology, Aix-Marseille Univ, C2VN, INSERM, INRAE, AP-HM CHU de la Conception, Marseille, France.

Alexandre Karras (A)

Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France.

Anne Moreau (A)

Pathology Department, CHU de Nantes, Nantes, France.

Jean-François Augusto (JF)

Department of Nephrology, CHU d'Angers, Angers, France.

Viviane Gnemmi (V)

Pathology Department, CHRU de Lille, Lille, France.

Hélène Perrochia (H)

Pathology Department, CHU de Montpellier, Montpellier, France.

Stanislas Bataille (S)

Institut Phocéen de Néphrologie, Clinique Bouchard, Marseille, France.

Moglie Le Quintrec (M)

Department of Nephrology, CHU de Montpellier, Montpellier, France.

Jean-Michel Goujon (JM)

Department of Pathology, CHU de Poitiers, Poitiers, France.

Samuel Rotman (S)

Service of Clinical Pathology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland.

Fadi Fakhouri (F)

Service of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

Classifications MeSH